Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 63 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: clozapine Clear all
Not listed Phase 4 Interventional

Clozapine Versus Olanzapine as Treatment for Comorbid Psychotic Disorder and Substance Use Disorder

NCT03857581
View directory record Official record
Conditions
Psychosis, Substance Use Disorders
Interventions
Clozapine, Olanzapine
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Evans, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Oct 17, 2026, 2:59 AM EDT
Terminated Phase 3 Interventional

Efficacy and Safety Study of Clozapine Augmented by Atomoxetine Versus Clozapine Augmented by Placebo in Patients With Chronic Resistant Schizophrenia

NCT00216281
View directory record Official record
Conditions
Schizophrenia
Interventions
Clozapine augmented with atomoxetine up to 40 mg or placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 26, 2013 · Synced Oct 17, 2026, 2:59 AM EDT
Withdrawn Phase 3 Interventional

Glycine and D-Cycloserine in Schizophrenia

NCT00000372
View directory record Official record
Conditions
Schizophrenia
Interventions
D-cycloserine, Glycine, Clozapine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 12, 2014 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors

NCT00178932
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression
Interventions
genetic analysis, genetic assay
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Phase 3 Interventional

Clozapine vs. Placebo in Treatment-Refractory Bipolar Disorder in Children and Adolescents

NCT00036582
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Clozapine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Phase 4 Interventional Results available

Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment

NCT00337350
View directory record Official record
Conditions
Schizophrenia
Interventions
rosiglitazone, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Not applicable Interventional

A Study of Strategies to Improve Schizophrenia Treatment

NCT00156637
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Team-Based Quality Improvement Intervention, Opinion Leader Intervention, Team Based Quality Improvement
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 65 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
4
States / cities
Fayetteville, Arkansas • No. Little Rock, Arkansas • Dayton, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 17, 2026, 2:59 AM EDT
Recruiting Phase 2Phase 3 Interventional

An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults

NCT03094429
View directory record Official record
Conditions
Refractory Schizophrenia
Interventions
NaBen®, Placebo
Drug · Other
Lead sponsor
SyneuRx International (Taiwan) Corp
Industry
Eligibility
18 Years to 55 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Phase 4 Interventional Results available

Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia

NCT00981526
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Telmisartan, Placebo, Clozapine, Olanzapine
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Phase 4 Interventional

Risperidone Augmentation in Patients With Schizophrenia

NCT00289861
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Oct 17, 2026, 2:59 AM EDT
Terminated Phase 4 Interventional

Alcoholism and Schizophrenia: Effects of Clozapine

NCT00169026
View directory record Official record
Conditions
Schizophrenia, Dual Diagnosis, Schizoaffective Disorder, Psychotic Disorder, Substance Abuse, Alcohol Abuse
Interventions
Clozapine versus typical (conventional) and atypical antipsychotic medications
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
19 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Jamaica Plain, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Phase 4 Interventional Results available

Minocycline Augmentation to Clozapine

NCT02124811
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Minocycline
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Not applicable Interventional

Accelerated Transcranial Magnetic Stimulation for People With Schizophrenia Treated With Clozapine

NCT06003036
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
sham stimulation, transcranial magnetic stimulation
Device
Lead sponsor
Deepak K. Sarpal, M.D.
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 17, 2026, 2:59 AM EDT
Recruiting Phase 4 Interventional

Biomarkers to Enhance Early Schizophrenia Treatment

NCT06969755
View directory record Official record
Conditions
Schizophenia Disorder
Interventions
aripiprazole, risperidone, clozapine
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 35 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
4
States / cities
Birmingham, Alabama • La Jolla, California • Belmont, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Pimozide Augmentation for Clozapine Partial Response

NCT00374244
View directory record Official record
Conditions
Schizophrenia
Interventions
Pimozide, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
2
States / cities
New Haven, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 4, 2016 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Phase 4 Interventional

A Placebo-Controlled Trial of Modafinil (Provigil) Added to Clozapine in Patients With Schizophrenia

NCT00573417
View directory record Official record
Conditions
Schizophrenia
Interventions
modafinil, Placebo
Drug
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 12, 2009 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Phase 4 Interventional

Treating Drug-Resistant Childhood Schizophrenia

NCT00048828
View directory record Official record
Conditions
Schizophrenia
Interventions
Olanzapine, Clozapine
Drug
Lead sponsor
Northwell Health
Other
Eligibility
10 Years to 18 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
3
States / cities
Dix Hills, New York • Glen Oaks, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Oct 17, 2026, 2:59 AM EDT
Terminated Phase 4 Interventional

Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia

NCT00169039
View directory record Official record
Conditions
Schizophrenia
Interventions
Clozapine, Chlorpromazine
Drug
Lead sponsor
Harvard Medical School (HMS and HSDM)
Other
Eligibility
19 Years to 60 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2002
U.S. locations
1
States / cities
Jamaica Plain, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 17, 2026, 2:59 AM EDT
Completed No phase listed Observational

FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey

NCT00683891
View directory record Official record
Conditions
Weight Gain, Sialorrhea
Interventions
FazaClo (clozapine, USP) ODT
Drug
Lead sponsor
Azur Pharma, Inc
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Costa Mesa, California • Gastonia, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 19, 2008 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Not applicable Interventional Results available

Adjunctive Minocycline in Clozapine Treated Schizophrenia Patients

NCT01433055
View directory record Official record
Conditions
Schizophrenia
Interventions
Minocycline, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 17, 2026, 2:59 AM EDT
Completed No phase listed Observational

YouScript IMPACT Registry

NCT02191358
View directory record Official record
Conditions
Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions
Not listed
Lead sponsor
Genelex Corporation
Industry
Eligibility
65 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 17, 2026, 2:59 AM EDT
Terminated Phase 2 Interventional Results available

Improving Metabolic Parameters of Antipsychotic Child Treatment With Ziprasidone, Aripiprazole, and Clozapine

NCT00617058
View directory record Official record
Conditions
Weight Gain
Interventions
metformin, healthy lifestyle intervention
Drug · Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
10 Years to 17 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 31, 2012 · Synced Oct 17, 2026, 2:59 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual

NCT00498550
View directory record Official record
Conditions
Schizophrenia, Dual Diagnosis, Schizoaffective Disorder, Psychotic Disorder, Cannabis Abuse
Interventions
Clozapine, Treatment as usual
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
4
States / cities
Los Angeles, California • Kansas City, Missouri • Manchester, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 17, 2026, 2:59 AM EDT
Completed No phase listed Observational

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

NCT02600741
View directory record Official record
Conditions
Schizophrenia
Interventions
Caregiver psycho-education and skills training, Caregiver support available at the study site, Paliperidone palmitate, Chlorpromazine, Droperidol, Fluphenazine, Haloperidol, Loxapine, Perphenazine, Pimozide, Prochlorperazine, Thiothixene, Thioridazine, Trifluoperazine, Aripiprazole, Asenapine, Clozapine, Iloperidone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Ziprasidone
Other · Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
34
States / cities
Bullhead City, Arizona • Oceanside, California • Denver, Colorado + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 17, 2026, 2:59 AM EDT